Loading…
CRBP
Corbus Pharmaceuticals Holdings, Inc.
NASDAQ· Healthcare· Biotechnology
$10.91-1.98%
Key metrics
- Market cap
- $211.01M
- P/E
- —
- Forward P/E
- —
- P/B
- 2.0x
- Dividend yield
- —
- EPS
- -$5.98
- ROE
- -95.58%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 2.62
- 52-week high
- $20.56
- 52-week low
- $7.12
History
How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
About the company
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
- 36
- Norwood, United States
Company description provided by Yahoo Finance.